Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Pablo Corral: The Interplay Between Lipoprotein(a) and Interleukin-6 in Determining Primary Cardiovascular Risk
Pablo Corral/LinkedIn
Apr 26, 2026, 05:43

Pablo Corral: The Interplay Between Lipoprotein(a) and Interleukin-6 in Determining Primary Cardiovascular Risk

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Johan Skov Bundgaard et al. published in Atherosclerosis, adding:

“Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting.

New data from UK Biobank (n=34,092): In primary prevention, the cardiovascular risk associated with elevated Lp(a) was significantly influenced by IL-6, a key upstream inflammatory cytokine.

  1. Higher Lp(a) increased MACE risk only when IL-6 was elevated (HR 1.17; 95% CI 1.07–1.28), while no significant association was seen when IL-6 was below median levels.
  2. Inflammation appears to amplify Lp(a) pathogenicity, supporting the concept that not all elevated Lp(a) carries the same biological risk burden.
  3. Hs-CRP did not show the same modifying effect, suggesting IL-6 may be a more informative biomarker than conventional inflammatory markers for Lp(a)-related risk stratification.
  4. Clinical implication: Future Lp(a)-lowering therapies may yield greatest benefit in individuals with concomitant elevated IL-6, enabling more precise preventive targeting.

Elevated Lp(a) appears to confer its greatest cardiovascular hazard in the presence of heightened IL-6–mediated inflammation, supporting a biologically integrated model in which inherited atherothrombotic burden and residual inflammatory risk act synergistically.”

Title: Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting

Authors: Johan Skov Bundgaard, Søren Albertsen Rand, Stefan Stender, Jesper Hastrup Svendsen, Pia Rengtved Lundegaard, Christian Erikstrup, Gustav Ahlberg, Ruth Frikke-Schmidt, Lars Dyrskjøt, Ole Halfdan Larsen, Henning Bundgaard, Jonas Ghouse

Pablo Corral

More posts featuring Pablo Corral on Hemostasis Today.

Atherosclerosis cardiovascular risk Christian Erikstrup Gustav Ahlberg Health Hematology Hemostasis Hemostasis News Hemostasis Today Henning Bundgaard interleukin-6 Jesper Hastrup Svendsen Johan Skov Bundgaard Jonas Ghouse Lars Dyrskjøt Lipoprotein(a) Medicine Ole Halfdan Larsen Pablo Corral Pia Rengtved Lundegaard Ruth Frikke-Schmidt Søren Albertsen Rand Stefan Stender UK Biobank
NewsFeed